Payment overview · 2025
General Payments
$325.84
14 reported records · 10 companies
Healthcare provider profile · identity verified
Laurel T Woods, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SEMINOLE, FL · NPI 1750432209
Verified facts
What the public records show
CMS Open Payments records show Laurel T Woods, M.D. received $325.84 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.35 | 18.8% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $49.22 | 15.1% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $43.72 | 13.4% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $38.39 | 11.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.77 | 8.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.98 | 7.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.35 | 6.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.35 | 5.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.34 | 5.9% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $18.37 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $325.84 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $61.35 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $49.22 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $43.72 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $38.39 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.77 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $23.41 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $18.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 396 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 214 | 83 |
| Losartan Potassium | Losartan Potassium | 196 | 64 |
| Lisinopril | Lisinopril | 149 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 148 | 57 |
| Gabapentin | Gabapentin | 132 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 34 |
| Simvastatin | Simvastatin | 120 | 37 |
| Omeprazole | Omeprazole | 118 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 36 |
| Metformin Hcl | Metformin Hcl | 111 | 36 |
| Trazodone Hcl | Trazodone Hcl | 100 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 30 |
| Metformin Hcl Er | Metformin Hcl | 71 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 18 |
| Furosemide | Furosemide | 64 | 22 |
| Alprazolam | Alprazolam | 57 | 19 |
| Baclofen | Baclofen | 56 | 13 |
| Bupropion Xl | Bupropion Hcl | 56 | 16 |
| Eliquis | Apixaban | 56 | 15 |
| Allopurinol | Allopurinol | 53 | 18 |
| Potassium Chloride | Potassium Chloride | 53 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 19 |
| Carvedilol | Carvedilol | 48 | 17 |
| Alendronate Sodium | Alendronate Sodium | 41 | 12 |
| Tramadol Hcl | Tramadol Hcl | 41 | 16 |
| Famotidine | Famotidine | 40 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 13 |
| Montelukast Sodium | Montelukast Sodium | 34 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | 11 |
| Valacyclovir | Valacyclovir Hcl | 32 | 14 |
| Estradiol | Estradiol | 31 | 11 |
| Finasteride | Finasteride | 31 | 12 |
| Sertraline Hcl | Sertraline Hcl | 31 | 12 |
| Valsartan | Valsartan | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | 11 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | 11 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | 12 |
| Ozempic | Semaglutide | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | 11 |
| Glipizide Er | Glipizide | 17 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $325.84 · 14 records | ABBVIE INC. | Dexcom G6 Transmitter, Doc Band, Heplisav-B, KISUNLA, NURTEC ODT, PAXLOVID, QULIPTA, SYNTHROID, TZIELD, UBRELVY, WATCHMAN Access System, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Synthroid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error